Psychedelic Science Newsletter
Issue #3September 22, 20257 studies

Ketamine works for depression but may damage the brain at higher doses

Ketamine works for depression but may damage the brain at higher doses

Monday, Monday, September 22nd Psychedelic Medicine Newsletter Issue #3

This week's research reveals both promise and caution around psychedelic medicine, with new insights on ketamine's therapeutic benefits versus potential neurotoxic risks, plus surprising findings about combining antidepressants with psychedelics.

🧠 Ketamine Shows Promise for Depression But Raises Neurotoxicity Concerns

A major review examined ketamine's brain safety across animal studies and human trials, revealing a critical dose-dependent pattern:

  • Animal studies show repeated high-dose ketamine causes lasting brain damage and memory problems, especially in young animals

  • Human trials of esketamine (up to 84 mg weekly) for depression showed maintained or slightly improved thinking over several years in adults

  • Recreational users taking high doses (over 1 gram daily) developed significant memory and decision-making impairments

Why this matters: The findings suggest ketamine's therapeutic window may be narrower than previously thought. While clinical doses appear safe for depression treatment, the research highlights serious risks when ketamine is used off-label at higher doses - a growing concern as ketamine clinics proliferate without standardized protocols.

🥇 Top 1% journal 🔗 American Journal of Psychiatry 🗓️ Sep 9

Key Findings

💊 You Might Not Need to Stop Antidepressants for Psychedelic Therapy

A comprehensive review of 18 studies found that combining antidepressants with classic psychedelics like psilocybin is generally safe, with no increased risk of dangerous serotonin syndrome. Some studies even showed significant improvements in depression symptoms while patients stayed on their regular medications, though the psychedelic effects might be somewhat reduced.

💡 Staying on antidepressants during psychedelic treatment could make these therapies accessible to more patients without the risks of medication withdrawal.
🎖️ Top 10% journal 🔗 Journal of Psychopharmacology 🗓️ Sep 11

🚑 Ketamine Group Therapy Helps Burned-Out Healthcare Workers

A 6-week ketamine-assisted group therapy program specifically targeted first responders and frontline healthcare workers dealing with work-related stress, trauma, and burnout - particularly those affected by COVID-19 pandemic pressures. The community-based approach combined ketamine's rapid-acting antidepressant effects with group psychotherapy support.

💡 Ketamine therapy might offer a targeted solution for occupational burnout in high-stress professions where traditional treatments fall short.

🍄 Psilocybin Therapy Reduces Suicidal Thoughts Across Multiple Studies

A systematic review and meta-analysis found that psilocybin therapy consistently reduced suicidal ideation in people with psychiatric diagnoses. The analysis examined multiple clinical trials and found significant improvements in suicidal thoughts, attempts, and deaths among participants receiving psilocybin treatment for various mental health conditions.

💡 Psilocybin therapy could become a crucial intervention for one of psychiatry's most urgent challenges - preventing suicide.
Top 20% journal 🔗 Therapeutic Advances in Psychopharmacology 🗓️ Sep 10

🧬 Brain Activity Changes in Autism Mirror Ketamine's Effects

Researchers compared brain activity in 405 autistic individuals versus 473 neurotypical controls and found consistent reductions in local brain activity, particularly in default mode network regions. Remarkably, the brain changes induced by ketamine (an NMDA receptor blocker) closely resembled the spatial patterns observed in autism, suggesting disrupted excitation-inhibition balance.

💡 Understanding autism's brain patterns through the lens of ketamine's effects could lead to new therapeutic approaches targeting the excitation-inhibition imbalance.
🥈 Top 2% journal 🔗 Nature Communications 🗓️ Sep 8

🔍 Street Psilocybin Edibles Contain Unknown Active Ingredients

A case series analyzing unregulated psilocybin mushroom edibles found significant variability in active constituents, raising safety concerns about products sold outside of clinical settings. The study evaluated the actual chemical composition of commercially available psilocybin edibles versus their labeled contents.

💡 The booming unregulated psychedelic market poses serious safety risks due to inconsistent dosing and unknown ingredients.
🥈 Top 2% journal 🔗 JAMA Network Open 🗓️ Sep 10

⚡ New Treatment Options Emerge for Treatment-Resistant Anxiety

A comprehensive review of 26 randomized trials and 36 studies identified multiple effective treatments for anxiety disorders that don't respond to standard therapy. The analysis found that switching between SSRIs, augmenting with antipsychotics like quetiapine, and using medications like pregabalin showed promise, while ketamine emerged as a potential option in open-label studies.

💡 Treatment-resistant anxiety isn't a dead end - multiple medication strategies and therapy approaches can still provide relief.
🥇 Top 1% journal 🔗 Psychotherapy and Psychosomatics 🗓️ Sep 13

Implications

This week's research paints a nuanced picture of psychedelic medicine's future: these treatments show remarkable promise for depression, anxiety, and suicidal ideation, but safety depends heavily on proper dosing and medical supervision. The field is moving toward more personalized approaches that could revolutionize mental healthcare - if we can navigate the risks responsibly.

Studies in this issue

Primary sources used for this newsletter.

  1. Ketamine's Benefits for Depression and Possible Brain Toxicity from Animal and Human Studies
    main storyThe American journal of psychiatry2025-09-10PMID 40926573
  2. Psilocybin therapy and its impact on suicidal thoughts, attempts, and deaths in people with mental health conditions
    key findingTherapeutic advances in psychopharmacology2025-09-11PMID 40933784
  3. Drug, therapy, and brain stimulation options for hard-to-treat anxiety disorders
    key findingPsychotherapy and psychosomatics2025-09-14PMID 40946318
  4. Using antidepressants and classic psychedelics together: An overview
    key findingJournal of psychopharmacology (Oxford, England)2025-09-12PMID 40937732
  5. Changes in local brain activity in autism relate to brain chemicals and ketamine effects
    key findingNature communications2025-09-09PMID 40925922
  6. Ketamine-Assisted Group Therapy for Work Stress in First Responders and Frontline Health Workers
    key findingPsychedelic medicine (New Rochelle, N.Y.)2025-09-11PMID 40933207
  7. Active Ingredients in Psilocybin Mushroom Edible Products
    key findingJAMA network open2025-09-11PMID 40932719

Continue reading

All Psychedelic Science issues